MNKD
MANNKIND CORP
NASDAQ · Healthcare · Biotechnology · US
$3.54
−1.12%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.08
- Revenue estimate
- $110.1M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$0.06
- EPS estimate
- -$0.01
- Revenue actual
- $109.4M
- Revenue estimate
- $108.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -264.4%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $11
- PT range
- $8.00 – $13
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.01 | -$0.06 | Miss -700.00% | $109.4M |
| May 6, 2026 | -$0.02 | -$0.05 | Miss -150.00% | $90.2M |
| Feb 26, 2026 | -$0.01 | -$0.05 | Miss -407.70% | $112.0M |
| Nov 5, 2025 | $0.01 | $0.03 | Beat 200.00% | $82.1M |
| Aug 6, 2025 | $0.04 | $0.00 | Miss -94.65% | $76.5M |
| May 8, 2025 | $0.03 | $0.04 | Beat 33.33% | $78.4M |
| Feb 26, 2025 | $0.03 | $0.03 | In line | $76.8M |
| Nov 7, 2024 | $0.06 | $0.04 | Miss -33.33% | $70.1M |
| Feb 27, 2024 | — | $0.02 | — | $58.5M |
| Feb 23, 2023 | -$0.06 | -$0.07 | Miss -16.67% | $36.1M |
| May 5, 2022 | -$0.10 | -$0.10 | In line | $12.0M |
| Feb 24, 2022 | -$0.06 | -$0.11 | Miss -83.33% | $12.5M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026